Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8273 versus erlotinib or gefitinib in first-line EGFR-mutated advanced NSCLC
NL-OMON44112Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing ASP8273, Erlotinib and Gefitinib (3 arms). Primary endpoint: Progression-free survival. Started Dec 2016; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44112.